NASDAQ:MASI - Masimo Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $261.17
  • Forecasted Upside: -0.08 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$261.37
▼ -0.39 (-0.15%)
1 month | 3 months | 12 months
Get New Masimo Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MASI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MASI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$261.17
▼ -0.08% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for Masimo in the last 3 months. The average price target is $261.17, with a high forecast of $310.00 and a low forecast of $201.00. The average price target represents a -0.08% upside from the last price of $261.37.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Masimo. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/27/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/25/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/22/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/21/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/19/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/14/2021Piper SandlerBoost Price TargetOverweight$280.00 ➝ $310.00High
i
10/28/2020Stifel NicolausBoost Price TargetBuy$255.00 ➝ $276.00High
i
10/28/2020Raymond JamesBoost Price TargetOutperform$250.00 ➝ $275.00High
i
Rating by Lawrence Keusch at Raymond James
10/28/2020Piper SandlerBoost Price TargetOverweight$250.00 ➝ $280.00High
i
10/6/2020Needham & Company LLCReiterated RatingHoldHigh
i
9/16/2020Raymond JamesReiterated RatingBuyLow
i
Rating by Lawrence Keusch at Raymond James
9/1/2020Robert W. BairdInitiated CoverageOutperform$260.00High
i
7/29/2020Stifel NicolausBoost Price TargetBuy$245.00 ➝ $255.00High
i
7/29/2020Raymond JamesBoost Price TargetOutperform$235.00 ➝ $250.00High
i
Rating by Lawrence Keusch at Raymond James
7/9/2020BTIG ResearchReiterated RatingHoldLow
i
6/26/2020Raymond JamesReiterated RatingBuyMedium
i
Rating by Lawrence Keusch at Raymond James
4/30/2020UBS GroupBoost Price TargetBuy$207.00 ➝ $245.00Medium
i
4/29/2020Stifel NicolausBoost Price TargetBuy$200.00 ➝ $245.00High
i
4/20/2020Needham & Company LLCDowngradeBuy ➝ HoldMedium
i
Rating by Michael Matson at Needham & Company LLC
4/1/2020Needham & Company LLCReiterated RatingBuy$201.00Low
i
Rating by Michael Matson at Needham & Company LLC
3/24/2020Needham & Company LLCReiterated RatingBuy$201.00Low
i
Rating by Michael Matson at Needham & Company LLC
3/2/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$183.00High
i
2/20/2020Piper SandlerBoost Price Target$175.00 ➝ $201.00Low
i
Rating by William Quirk at Piper Sandler
2/20/2020Needham & Company LLCBoost Price TargetBuy$182.00 ➝ $201.00Medium
i
2/20/2020UBS GroupBoost Price TargetBuy$190.00 ➝ $207.00Medium
i
1/15/2020Piper SandlerReiterated RatingBuy$175.00Low
i
Rating by William Quirk at Piper Sandler
1/15/2020UBS GroupBoost Price TargetBuy$180.00 ➝ $190.00High
i
12/17/2019Piper Jaffray CompaniesReiterated RatingOverweight$161.00 ➝ $175.00Low
i
8/1/2019Stifel NicolausBoost Price TargetBuy$165.00 ➝ $170.00Medium
i
8/1/2019UBS GroupBoost Price TargetBuy$172.00 ➝ $180.00Medium
i
8/1/2019BTIG ResearchReiterated RatingHoldHigh
i
5/17/2019Stifel NicolausBoost Price TargetBuy$150.00 ➝ $160.00Low
i
5/17/2019Piper Jaffray CompaniesBoost Price Target$148.00 ➝ $160.00Low
i
5/7/2019UBS GroupBoost Price TargetBuy ➝ Buy$147.00 ➝ $160.00High
i
5/7/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$155.00 ➝ $158.00High
i
5/7/2019Piper Jaffray CompaniesBoost Price TargetOverweight$140.00 ➝ $148.00High
i
4/16/2019BTIG ResearchDowngradeBuy ➝ Neutral$134.50High
i
4/9/2019Needham & Company LLCReiterated RatingBuyLow
i
3/13/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$148.00 ➝ $155.00Medium
i
2/27/2019Piper Jaffray CompaniesReiterated RatingOverweight$140.00High
i
2/1/2019Needham & Company LLCReiterated RatingBuy$139.00Low
i
12/19/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$120.00Medium
i
11/27/2018UBS GroupInitiated CoverageBuy$137.00High
i
11/1/2018Piper Jaffray CompaniesBoost Price TargetNeutral$120.00High
i
10/2/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$112.00 ➝ $145.00Low
i
9/14/2018Needham & Company LLCInitiated CoverageBuy ➝ BuyHigh
i
8/2/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$108.00 ➝ $112.00High
i
5/3/2018BTIG ResearchReiterated RatingBuy$100.00High
i
5/2/2018Piper Jaffray CompaniesBoost Price TargetNeutral$94.00High
i
3/9/2018BarclaysInitiated CoverageOverweight ➝ Overweight$97.00Medium
i
3/1/2018Piper Jaffray CompaniesReiterated RatingHold$91.00High
i
11/3/2017Stifel NicolausReiterated RatingBuy$108.00N/A
i
8/14/2017BTIG ResearchUpgradeNeutral ➝ Buy$100.00Medium
i
8/3/2017Stifel NicolausReiterated RatingBuy$105.00 ➝ $108.00High
i
7/19/2017Roth CapitalBoost Price TargetBuy$96.00 ➝ $105.00Low
i
7/10/2017Stifel NicolausInitiated CoverageBuy$105.00High
i
5/22/2017WedbushReiterated RatingOutperform$112.00Low
i
4/4/2017WedbushReiterated RatingOutperform ➝ Outperform$100.00Low
i
3/16/2017Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralHigh
i
2/27/2017WedbushReiterated RatingOutperform ➝ Outperform$95.00N/A
i
2/13/2017Raymond JamesDowngradeOutperform ➝ Market PerformN/A
i
2/13/2017CitigroupDowngradeMarket Perform$60.00N/A
i
2/13/2017WedbushBoost Price TargetOutperform$85.00N/A
i
11/14/2016WedbushReiterated RatingOutperform$75.00N/A
i
11/3/2016WedbushReiterated RatingOutperform$63.00N/A
i
8/5/2016Piper Jaffray CompaniesReiterated RatingOverweight$52.00 ➝ $55.00N/A
i
8/5/2016BTIG ResearchReiterated RatingHoldN/A
i
Rating by Sean Lavin at BTIG Research
8/4/2016WedbushReiterated RatingOutperform$60.00 ➝ $63.00N/A
i
6/1/2016Raymond JamesDowngradeStrong-Buy ➝ OutperformN/A
i
5/5/2016WedbushBoost Price TargetOutperform$51.00 ➝ $57.00N/A
i
5/5/2016Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$43.00 ➝ $52.00N/A
i
5/5/2016Roth CapitalBoost Price TargetBuy$40.00 ➝ $50.00N/A
i
Rating by Chris Lewis at Roth Capital
3/1/2016BTIG ResearchReiterated RatingNeutralN/A
i
2/26/2016Raymond JamesLower Price TargetOutperform$46.00 ➝ $44.00N/A
i
2/24/2016Roth CapitalReiterated RatingBuyN/A
i
Rating by Chris Lewis at Roth Capital
2/24/2016WedbushReiterated RatingOutperform$51.00N/A
i
(Data available from 1/17/2016 forward)
Masimo logo
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. Additionally, the company offers Trace, a patient data visualization and reporting software for Masimo Root and Radical-7 monitors. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, home care providers, long term care facilities, veterinarians, and consumers. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $261.37
$260.58
$266.60

50 Day Range

MA: $267.28
$253.07
$283.75

52 Week Range

Now: $261.37
$143.90
$284.86

Volume

277,499 shs

Average Volume

228,510 shs

Market Capitalization

$14.39 billion

P/E Ratio

67.89

Dividend Yield

N/A

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Masimo?

The following sell-side analysts have issued reports on Masimo in the last twelve months: BTIG Research, Needham & Company LLC, Piper Sandler, Raymond James, Robert W. Baird, Stifel Nicolaus, UBS Group AG, and Zacks Investment Research.

What is the current price target for Masimo?

6 Wall Street analysts have set twelve-month price targets for Masimo in the last year. Their average twelve-month price target is $261.17, suggesting a possible downside of 0.1%. Piper Sandler has the highest price target set, predicting MASI will reach $310.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $201.00 for Masimo in the next year.

What is the current consensus analyst rating for Masimo?

Masimo currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MASI will outperform the market and that investors should add to their positions of Masimo.

What other companies compete with Masimo?

How do I contact Masimo's investor relations team?

Masimo's physical mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider's listed phone number is 949-297-7000 and its investor relations email address is ekammerman@masimo.com. The official website for Masimo is www.masimo.com.